NOT KNOWN DETAILS ABOUT HEMGENIX

Amount of eligible patients: CDEC mentioned the uncertainty in the quantity of individuals with moderately critical to intense hemophilia B in Canada suitable for etranacogene dezaparvovec. Clinical experts consulted by CADTH indicated that some clients who're categorized as getting mild or moderate ailment may have a critical bleeding phenotype, w